Skip to main content

Advertisement

Table 1 Disposition of patients

From: A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus

Study medication disposition, n (%) Omarigliptin 25 mg N = 2100 Placebo N = 2102
Did not take study medication 8 (0.4) 2 (0.1)
Discontinued study medication 2092 (99.6) 2100 (99.9)
 Adverse event 88 (4.2) 74 (3.5)
 Death 48 (2.3) 37 (1.8)
 Lack of efficacy 9 (0.4) 14 (0.7)
 Lost to follow-up 44 (2.1) 54 (2.6)
 Non-compliance with study drug 10 (0.5) 6 (0.3)
 Physician decision 25 (1.2) 33 (1.6)
 Progressive disease 2 (0.1) 1 (0.0)
 Protocol violation 7 (0.3) 14 (0.7)
 Study terminated by sponsor 1615 (76.9) 1602 (76.2)
 Withdrawal by patient 197 (9.4) 213 (10.1)
 Other 47 (2.2) 52 (2.5)